ESMO/LinkedIn
Jun 13, 2025, 03:50
Philippe Aftimos Discusses ctDNA and Molecular Profiling Guiding Therapy for HR+/HER2- Breast Cancer in the ESMO Daily Reporter
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Metastatic Breast Cancer: Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations.
Read the opinion by Philippe Aftimos in the ESMO Daily Reporter discussing the results of these positive pivotal randomised trials confirming the important role of Molecular Profiling to guide therapy and the emerging role of ctDNA in the detection and targeting of resistance mechanisms.”
More posts featuring ESMO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 26, 2025, 08:40
Jul 26, 2025, 08:13
Jul 26, 2025, 07:32
Jul 26, 2025, 06:44
Jul 26, 2025, 06:11
Jul 26, 2025, 04:02
Jul 26, 2025, 03:52
Jul 26, 2025, 03:45
Jul 26, 2025, 03:33